Compare Merck & Co., Inc. (MRK) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Raytheon Technologies Corp — how do they compare? Merck & Co., Inc. trades at $148.1 (market cap $366.28B), while Raytheon Technologies Corp trades at $197.92 (market cap $267.95B). The key difference: Merck & Co., Inc. is the larger of the two by market cap, and Merck & Co., Inc. pays the higher dividend (2.29%). Which is the better fit depends on your goals.
| MRK | RTX | |
|---|---|---|
Market Cap | $366.28B | $267.95B |
Sector | Health | Industrials |
52-Week High | $156.43 | $225.49 |
52-Week Low | $77.60 | $155.00 |
Enterprise Value | $413.04B | $298.50B |
Dividend Yield | 2.29% | 1.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
RTX trades at $197.55, down 1.61% today, but maintains a bullish technical outlook with strong support near $197 and resistance at $200. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.75. Revenue growth accelerated to $88.6 billion in 2025, with net income reaching $6.73 billion. Recent contract wins include a $515 million U.S. Navy radar award announced June 3, 2026.
Outlook remains positive with 65% analyst buy ratings and a $235.33 price target implying 19% upside. Key risks include execution challenges in scaling munitions production and dependence on defense budgets. Strong cash flow generation and expanding margins support continued dividend payments, with the next $0.73 dividend payable September 3, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
